2023-509256-34-00
CTIS ↗
BEAM-302
Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease
biotech · Sleep · T-Cell Acute Lymphoblastic Leukemia/Lymphoma · BEAM
Beam Therapeutics
Beam Therapeutics trial registry — 10 ClinicalTrials.gov studies with program phase, status, and indication context.
Cambridge, USA HQ
2017 Founded
573 Employees
Public company Type
BEAM · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2017
- Employees
- 573
- Programs
- 10
- Drugs
- 14
- Patents
- 14
Beam Therapeutics clinical trials
Registry index of 10 ClinicalTrials.gov studies linked to Beam Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Beam Therapeutics trial registry — 10 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Beam Therapeutics.
-
Beam Organics Dream Powder — Unknown
Clinical update -
BEAM Dream Powder — Unknown
Clinical update -
BEAM-301: Single dose of BEAM-301 administered by IV — Phase 2
Clinical update -
Allogeneic anti-CD7 CAR-T cells (BEAM-201) — Phase 1
Clinical update -
PRDR — Unknown
Clinical update -
BEAM-302 — Phase 2
Clinical update -
BEAM-302 — Phase 2
Clinical update -
BEAM-201 — Phase 2
Clinical update